Site icon OncologyTube

Debate: Salvage therapy for mCRC? Regorafenib followed by TAS-102

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred salvage therapy for metastatic colorectal cancer (mCRC) is regorafenib followed by TAS-102.

A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205

© 2016 Imedex, LLC.

Advertisement
Exit mobile version